Jan 8 2010
TetraLogic Pharmaceuticals announced today that the Company has
completed dosing of the first cohort in a Phase 1 clinical trial of its
selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label,
dose-escalation study evaluating the safety and tolerability of TL32711
in adults with solid tumors or lymphoma refractory to standard
therapies. The study will also assess the pharmacokinetics,
pharmacodynamics and anti-tumor activity of TL32711.
“This is an important milestone for our Company and for cancer
patients”
“This is an important milestone for our Company and for cancer
patients,” said John M. Gill, President and Chief Executive Officer of
TetraLogic Pharmaceuticals. “The ability of TL32711 to antagonize
Inhibitor of Apoptosis Proteins in a selective manner represents a new
broadly applicable approach to treat cancers that are normally resistant
to therapies.”
Source TetraLogic Pharmaceuticals